Literature DB >> 7692464

Clinical and US findings in prostate cancer: patients with normal prostate-specific antigen levels.

J A Spencer1, A A Alexander, L Gomella, T Matteucci, B B Goldberg.   

Abstract

PURPOSE: To determine guidelines for biopsy in men with normal prostate-specific antigen (PSA) levels and suspected prostate cancer.
MATERIALS AND METHODS: The clinical-sonographic features of 91 lesions of reduced echogenicity in 83 men with normal PSA levels who underwent transrectal ultrasound-guided biopsy were analyzed.
RESULTS: Sixteen men (19%) had cancer, two with bilateral foci, and four had prostatic intraepithelial neoplasia (PIN). Fourteen of 47 discrete hypoechoic lesions yielded cancer or PIN versus only five of 44 ill-defined vaguely hypoechoic lesions (P = .03). Fifteen of 18 malignant lesions exceeded 1 cm in longest dimension. In 47 men, sonographic and digital rectal examination (DRE) findings corresponded; 17 (36%) had cancer or PIN. By contrast, of 36 patients with differing sonographic and DRE findings, only three (8%) had malignancy at biopsy (P < .01).
CONCLUSION: Predictors of malignancy at sonography of the peripheral prostate gland in men with normal PSA levels include (a) lesion size, (b) degree and focality of hypoechogenicity, and (c) correspondence with the site of DRE abnormality.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692464     DOI: 10.1148/radiology.189.2.7692464

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Factors influencing the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography: correlation with biopsy and radical prostatectomy specimens.

Authors:  J Jiang; Y-Q Chen; Y-K Zhu; X-H Yao; J Qi
Journal:  Br J Radiol       Date:  2012-06-14       Impact factor: 3.039

2.  [New ultrasound technologies for the diagnostics of prostate cancer].

Authors:  T de Zordo; M Ladurner; W Horninger; S W Heijmink; W Jaschke; F Aigner; F Frauscher
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.